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Abstract  
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) psoriatic 
arthritis ‘Outcome Measures in Rheumatology’(OMERACT) working group presented a review 
of the progress made at the 2014 OMERACT meeting.  At OMERACT members of the working 
group presented work from the Patient Involvement in Outcome Measures for Psoriatic Arthritis 
(PIOMPSA) group to improve the incorporation of patient research partners in psoriatic arthritis 
outcomes research, the results of discussions within the OMERACT breakout groups and finally 
the voting results.  OMERACT meeting participants endorsed the need to update the psoriatic 
arthritis core set according to the Filter 2.0 framework.  The workshop breakout group 
discussions identified opportunities the core set revision would allow, including the potential of 
consolidating existing redundancy within the core set, improved incorporation of the patient 
perspective and the possibility of including disease impact such as fatigue in to the inner circle.  
The GRAPPA working group has now set out a program of research to update the core set with 
the aim of seeking endorsement at OMERACT 2016.  
 
 
  
Introduction 
The psoriatic arthritis (PsA) core set for outcome measures to be used in randomized controlled 
trials (RCTs) and longitudinal observational studies was endorsed at Outcome Measures in 
Rheumatology (OMERACT) 8 in Malta.1  Considerable work within the Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been undertaken over the last 
eight years to develop appropriate individual and composite responder indices to capture disease 
activity.2, 3  At the OMERACT 10 meeting in 2012 it became clear that much of this work had 
been undertaken with little or no incorporation of the patient perspective.  Incorporation of the 
patient perspective through meaningful, ongoing inclusion of patient research partners throughout 
the outcome measure development and domain selection process has acknowledged benefits.  
The role of patients in outcome research is embedded at the heart of the OMERACT process.4, 5  
Prior examples of the benefits of this approach include the ability to determine the minimum 
clinically important differences (MCID) in patient reported outcomes, development of definitions 
of remission and flare and inclusion of fatigue and participation to the “core set” in rheumatoid 
arthritis.6, 7  A number of initiatives on both sides of the Atlantic are underway to firmly embed 
incorporation of the patient perspective in wider health research.  The National Institutes of 
Health (NIH) has established the Patient Centered Outcomes Research Institute (PCORI) project, 
the National Institute of Health Research (NIHR) in the United Kingdom has convened the 
INVOLVE group to promote patient involvement in the National Health Service (NHS) and the 
European League Against Rheumatism (EULAR) has published recommendations for the 
inclusion of the patient perspective in research.8  At this GRAPPA annual meeting the psoriatic 
arthritis OMERACT working group presented a summary of the work of the PIOMPSA group 
over the last two years, the results of the breakout group discussions and attendee voting at 
OMERACT 12 and a potential roadmap towards endorsement of a revised core set OMERACT 
13 in 2016.   
 
Presentations 
The OMERACT 12 Psoriatic Arthritis working group overview 
Dr Niti Goel introduced the PsA OMERACT working group; comprised of two fellows, four co-
chairs, three patient research partners, one member of the OMERACT executive for liaison and 
two additional GRAPPA member attendees (see acknowledgments).  The PsA workshop 
consisted of presentations of the work undertaken since OMERACT 10 including the Patient 
Outcome Measures for Psoriatic Arthritis (PIOMPSA) initiative,9 the Psoriatic Arthritis Impact of 
Disease (PsAID) study10 and the progress made towards development of composite disease 
activity measures.2  The presentations were followed by discussion in breakout groups on the 
need to update the PsA core set and what revisions should be considered.  Results for the 
breakout group were presented at the plenary followed by voting (report in press).11   
 
Review of the patient involvement initiative- PIOMPSA  
The PIOMPSA effort was initiated in 2012 to improve incorporation of the patient perspective in 
PsA outcomes research within GRAPPA.  The first meeting in Dublin, Ireland included equal 
numbers of rheumatologists and patient research partners and efforts have been made to preserve 
this balance to give patient research partners an equal voice at the proceedings.9  The PIOMPSA 
group discussed the relative lack of patient input in the development of the PsA core-set and 
outcome measure development and undertook a systematic literature review to define levels of 
patient involvement thus far together with a roadmap to enhance integration of patient 
perspectives in future research in PsA.  The group identified a potential need to revise the 
existing PsA core set. This was primarily to ensure incorporation of patient involvement in the 
domain selection and prioritisation but additionally to incorporate the considerable research 
progress from 2006 onward which could inform revision of the domains constructs including;  
 The 68/66 (tender/swollen) joint count having been identified as the optimal joint count 
for PsA assessment in clinical trials.12   
 Tools to assess fatigue, enthesitis, dactylitis and the measurement of axial disease haing 
been developed and tested.13, 14, 15 
 The Psoriasis Activity and Severity Index (PASI) having been shown to be reliable when 
performed by rheumatologists or dermatologists.16   
Updating the core set in light of these research findings would allow patient representation and an 
opportunity for movement or incorporation of domains important to patients such as fatigue, 
dactylitis and participation (work/ leisure activities) that were not previously included.9, 17  Dr 
Goel summarised with an acknowledgment that the patient research partner role within GRAPPA 
needed to be formalised through the work done of the Building Bridges initiative.   
 
Update of the PsA core set, breakout group discussion and voting 
Dr Tillett reviewed the results of the OMERACT 12 breakout discussions and voting.  The 
existing PsA core set, endorsed at OMERACT 8 in 2006, was reviewed (figure 1)1 and compared 
with the new OMERACT filter 2.0.18  The new structure encourages researchers to consider 
domains within four ‘core areas’: pathophysiological manifestations, life impact, resource use 
and death. (figure 2).18  Domains are then placed within concentric spheres by decreasing 
importance and/or availability of applicable instruments and finally for the research agenda.  The 
core (central) sphere should contain at least one domain of each core area (pathophysiological 
manifestations, life impact, resource use and death).  The middle sphere could contain a choice of 
additional domains dependent on the individual study question and the final outer sphere reserved 
for additional domains of interest in the research agenda.  Participants at the OMERACT 
workshop breakout groups were given a copy of the existing PsA core set and asked to consider 
the need for its revision and if so what changes to consider. 
 
Feedback from the breakout groups identified a number of themes. There was general agreement 
that there was a need to revise the PsA core set and this would present opportunities to improve 
the existing core set.  Within the ‘core area’ of ‘pathophysiology’ there was considered to be an 
opportunity to amend existing redundancy.  An umbrella term such as ‘inflammatory 
musculoskeletal disease’ for arthritis, enthesitis, dactylitis and axial disease could be considered.  
‘Psoriasis activity’ may be considered as an encompassing term for skin and nail disease and 
‘biomarkers’ for acute phase reactants. ‘Life impact’ concepts emerging from the breakout 
discussions included a strong message to retain pain, health related quality of life (HRQOL), 
function and patient global in the core set while adding fatigue which attendees noted had also 
been ranked highly in the PsAID study.10  There was debate regarding the potential overlap of 
domains captured in the patient global measure as well as fatigue.  There was recognition of the 
increasing evidence that it is legitimate to move items like dactylitis19, fatigue20 and enthesitis21 
from former positions in the second circle to higher prioritization in the inner circle, especially as 
tools had been developed and tested since the initial core set creation to evaluate these.  
 
The proposal to revise the PsA core set was strongly endorsed with a 100% vote by the 
OMERACT workshop participants and was notably the first time a unanimous vote had been 
achieved within OMERACT.  The PsA core set will therefore be the first to undergo revision 
using the OMERACT Filter 2.0.  Consensus was also achieved on retaining the patient global 
within the core set (endorsed with 70% vote) as well as adding fatigue (endorsed with 72% vote).   
 
Conclusion 
At the OMERACT 12 PsA workshop there was unanimous endorsement for the need to update 
the PsA core set. The results of the OMERACT breakout group discussions highlighted 
opportunities to involve patients as well as add, move or merge existing domains to improve 
existing redundancy.  Work over the next two years will focus on the revision of the PsA core set 
according to the filter 2.0 with the aim of seeking endorsement at OMERACT 13 in 2016.  
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Figure 1 
 
Domains for PsA (duplicated with kind permission)1 
  
Figure  2
 
Conceptual framework for core areas (duplicated with kind permission)18.  
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